<DOC>
	<DOC>NCT01425320</DOC>
	<brief_summary>This study will investigate the pharmacokinetics, safety and tolerability of dapsone and adapalene following topical administration of 2 formulations of dapsone/adapalene fixed combination gel, dapsone 5% gel (ACZONE®), and adapalene 0.3% gel (Differin®) in subjects with acne vulgaris.</brief_summary>
	<brief_title>Pharmacokinetics Study of Dapsone-Adapalene Fixed Combination Gel in Acne</brief_title>
	<detailed_description />
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Dapsone</mesh_term>
	<mesh_term>Adapalene</mesh_term>
	<criteria>Moderate acne on the face Willing to avoid swimming during the study Willing to avoid excessive sunlight and ultraviolet light (e.g., tanning beds)during the study Willing to avoid moisturizers, sunscreens, cosmetics, and chemical peels during the study Severe cystic acne Use of topical or oral retinoids within 4 weeks Use of isotretinoin within 3 months Use of dapsone or adapalene within 3 months Anticipated need to engage in activities/exercise that would cause profuse sweating Donated blood or equivalent blood loss within 90 days</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>